Trial · NCT03990363
Results by group56
Each measurement the trial posted, group by group, in the words and numbers it posted.
21 to 40 of 56
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Estimated Glomerular Filtration Rate (eGFR) (mL/Min/1.73 m²) Change From Baseline at 6 Months (V8), Repeated Measures Mixed Model (MMRM) | High Dose Versus Allopurinol | 1.023 | 95% Confidence Interval 0.9773 to 1.070 | mL/min/1.73 m² | |
| Estimated Glomerular Filtration Rate (eGFR) (mL/Min/1.73 m²) Change From Baseline at 6 Months (V8), Repeated Measures Mixed Model (MMRM) | Interemdiate Dose Versus Allopurinol | 0.9859 | 95% Confidence Interval 0.9429 to 1.031 | mL/min/1.73 m² | |
| Estimated Glomerular Filtration Rate (eGFR) (mL/Min/1.73 m²) Change From Baseline at 6 Months (V8), Repeated Measures Mixed Model (MMRM) | Low Dose Versus Allopurinol | 1.024 | 95% Confidence Interval 0.9786 to 1.071 | mL/min/1.73 m² | |
| Estimated Glomerular Filtration Rate (eGFR) (mL/Min/1.73 m²) Change From Baseline at 6 Months (V8), Repeated Measures Mixed Model (MMRM) | Allopurinol Versus Placebo | 0.9868 | 95% Confidence Interval 0.9436 to 1.032 | mL/min/1.73 m² | |
| Estimated Glomerular Filtration Rate (eGFR) (mL/Min/1.73 m²) Change From Baseline at 12 Months (Visit 10) | High Dose | 0.9809 | Geometric Coefficient of Variation 20.09 | mL/min/1.73 m² | |
| Estimated Glomerular Filtration Rate (eGFR) (mL/Min/1.73 m²) Change From Baseline at 12 Months (Visit 10) | Intermediate Dose | 0.9454 | Geometric Coefficient of Variation 21.24 | mL/min/1.73 m² | |
| Estimated Glomerular Filtration Rate (eGFR) (mL/Min/1.73 m²) Change From Baseline at 12 Months (Visit 10) | Low Dose | 0.9613 | Geometric Coefficient of Variation 17.59 | mL/min/1.73 m² | |
| Estimated Glomerular Filtration Rate (eGFR) (mL/Min/1.73 m²) Change From Baseline at 12 Months (Visit 10) | Switch Dose PA5 | 1.101 | Geometric Coefficient of Variation 27.23 | mL/min/1.73 m² | |
| Estimated Glomerular Filtration Rate (eGFR) (mL/Min/1.73 m²) Change From Baseline at 12 Months (Visit 10) | Allopurinol | 0.9593 | Geometric Coefficient of Variation 23.36 | mL/min/1.73 m² | |
| Estimated Glomerular Filtration Rate (eGFR) (mL/Min/1.73 m²) Change From Baseline at 12 Months (Visit 10) | Placebo | 0.9469 | Geometric Coefficient of Variation 23.33 | mL/min/1.73 m² | |
| S-creatinine (mg/dL) Change From Baseline at 6 Months (V8), Repeated Measures Mixed Model (MMRM) | High Dose Versus Placebo | 0.9888 | 95% Confidence Interval 0.9523 to 1.027 | Geometric Mean Ratio | |
| S-creatinine (mg/dL) Change From Baseline at 6 Months (V8), Repeated Measures Mixed Model (MMRM) | Intermediate Dose Versus Placebo | 1.023 | 95% Confidence Interval 0.9857 to 1.062 | Geometric Mean Ratio | |
| S-creatinine (mg/dL) Change From Baseline at 6 Months (V8), Repeated Measures Mixed Model (MMRM) | Low Dose Versus Placebo | 0.9901 | 95% Confidence Interval 0.9538 to 1.028 | Geometric Mean Ratio | |
| S-creatinine (mg/dL) Change From Baseline at 6 Months (V8), Repeated Measures Mixed Model (MMRM) | High Dose Versus Allopurinol | 0.9801 | 95% Confidence Interval 0.9437 to 1.018 | Geometric Mean Ratio | |
| S-creatinine (mg/dL) Change From Baseline at 6 Months (V8), Repeated Measures Mixed Model (MMRM) | Interemdiate Dose Versus Allopurinol | 1.014 | 95% Confidence Interval 0.9770 to 1.053 | Geometric Mean Ratio | |
| S-creatinine (mg/dL) Change From Baseline at 6 Months (V8), Repeated Measures Mixed Model (MMRM) | Low Dose Versus Allopurinol | 0.9814 | 95% Confidence Interval 0.9452 to 1.019 | Geometric Mean Ratio | |
| S-creatinine (mg/dL) Change From Baseline at 6 Months (V8), Repeated Measures Mixed Model (MMRM) | Allopurinol Versus Placebo | 1.009 | 95% Confidence Interval 0.9718 to 1.047 | Geometric Mean Ratio | |
| S-creatinine (mg/dL) Change From Baseline at 12 Months (Visit 10) | High Dose | 1.011 | Geometric Coefficient of Variation 18.57 | mg/dL | |
| S-creatinine (mg/dL) Change From Baseline at 12 Months (Visit 10) | Intermediate Dose | 1.038 | Geometric Coefficient of Variation 18.37 | mg/dL | |
| S-creatinine (mg/dL) Change From Baseline at 12 Months (Visit 10) | Low Dose | 1.026 | Geometric Coefficient of Variation 17.15 | mg/dL |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03990363/results?page=2